Literature DB >> 1596308

Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100.

A Corsini1, M Mazzotti, A Villa, F M Maggi, F Bernini, L Romano, C Romano, R Fumagalli, A L Catapano.   

Abstract

To verify whether the LDL receptors from different animal species recognize the binding domain of human apo B-100 we studied the interaction of LDL from control and familial binding defective apo B-100 (FDB) with cultured cells. Human, monkey, bovine, guinea pig and rabbit LDL receptors distinguish between normal and binding defective LDL with a displacement ratio (defective/normal) of 3.3, 2.6, 3.4, 3.1 and 2.0, respectively. Guinea pig and rabbit receptors, however, showed affinities 2-3-fold lower than the human receptor. Hamster, rat and mouse cells failed to differentiate between normal and FDB LDL with a ratio of 1.2, 0.8, and 1.4; the apparent affinities were 4-8 times lower than that of the human receptor. The data from the latter species suggest that the LDL receptor recognizes an area of human apo B different from the human receptor binding domain. The ability of antibody Mb47 to inhibit the binding of human LDL to human, rabbit and guinea pig but not to mouse cells further stresses this concept. Moreover, in 17 alpha-ethinyl estradiol-treated rats the rate of disappearance from plasma of FDB and control 125I-labelled LDL was identical, thus confirming the in vitro observations. These data suggest that the binding domain of the LDL receptor is functionally conserved in man, monkey, cow, rabbit and guinea pig, but is quite distinct in rat, mouse and hamster.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596308     DOI: 10.1016/0021-9150(92)90203-s

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  SR-BI (Scavenger Receptor BI), Not LDL (Low-Density Lipoprotein) Receptor, Mediates Adrenal Stress Response-Brief Report.

Authors:  Misa Ito; Xiang Ye; Qian Wang; Ling Guo; Dan Hao; Deborah Howatt; Alan Daugherty; Lei Cai; Ryan Temel; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-06-11       Impact factor: 8.311

2.  Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia.

Authors:  Christopher Jones; Rita Garuti; Peter Michaely; Wei-Ping Li; Nobuyo Maeda; Jonathan C Cohen; Joachim Herz; Helen H Hobbs
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).

Authors:  M F Linton; R V Farese; G Chiesa; D S Grass; P Chin; R E Hammer; H H Hobbs; S G Young
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

4.  Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors.

Authors:  Li Li; Patricia A Thompson; Richard L Kitchens
Journal:  J Lipid Res       Date:  2008-05-22       Impact factor: 5.922

5.  Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a).

Authors:  M J Callow; J Verstuyft; R Tangirala; W Palinski; E M Rubin
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

6.  Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice.

Authors:  M J Callow; L J Stoltzfus; R M Lawn; E M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

7.  Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation.

Authors:  Maria Luz Fernandez; Jeff S Volek
Journal:  Nutr Metab (Lond)       Date:  2006-03-27       Impact factor: 4.169

8.  Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice.

Authors:  Päivi A Teivainen; Knut A Eliassen; Edward M Rubin; Srdjan Djurovic; Kåre Berg
Journal:  Lipids Health Dis       Date:  2004-05-11       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.